Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

INDUSTRY × Glioblastoma × tempol × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Prostatic Neoplasms 1 Prostate Cancer Recurrent 1 Ototoxicity 1 Neoplasm Metastasis 1 Mucositis 1 Glioblastoma 1

Interventions

Temozolomide 86 Bevacizumab 37 Radiotherapy 34 Lomustine 18 Radiation 16 Surgical Procedures, Operative 8 Carboplatin 8 pembrolizumab 7 Irinotecan 7 Carmustine 7 Nivolumab 6 Granulocyte-Macrophage Colony-Stimulating Factor 6 Flucytosine 6 vocimagene amiretrorepvec 5 depatuxizumab mafodotin 5 IL13-PE38 5 ABT-414 5 veledimex 4 sargramostim 4 NVP-BKM120 4 Gemcitabine 4 Dianhydrogalactitol 4 Cyclophosphamide 4 Chlorotoxin 4 Aminolevulinic Acid 4 selinexor 3 rindopepimut 3 olinvacimab 3 enzastaurin 3 Valacyclovir 3

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04874506 2021-05-05

MBM-02 (Tempol) for the Treatment of Glioblastoma Multiforme (GBM)

Matrix Biomed, Inc.

Phase 2 Unknown

Glioblastoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡